MétaCan
Menu
Back to cohort
Record W4249204234 · doi:10.1186/s12931-018-0930-9

Abstracts from the 2018 Respiratory Effectiveness Group Summit

2018· article· en· W4249204234 on OpenAlexaff

Bibliographic record

VenueRespiratory Research · 2018
Typearticle
Languageen
FieldMedicine
TopicChronic Obstructive Pulmonary Disease (COPD) Research
Canadian institutionsTD Bank GroupUniversity of Toronto
FundersHealth Research Council of New ZealandSunovionHandokSanofiRegeneron PharmaceuticalsTeva Pharmaceutical IndustriesGenentechAstraZenecaMylanGlaxoSmithKlineAmgen
KeywordsWheezeSummitAsthmaMedicineRespiratory systemLog-rank testPrimary carePediatricsInternal medicineSurvival analysisFamily medicineGeographyCartography

Abstract

fetched live from OpenAlex

Background: Asthma and chronic obstructive pulmonary disease (COPD) have traditionally been viewed as distinct disorders.Past studies have often focused on specific aspects of each disease based on a single diagnostic label, with strict clinical trial enrolment criteria and limited generalisability.There are few prospective, observational studies that include patients across asthma, COPD and asthma-COPD overlap diagnoses.Consequently, the ways in which these different clinical profiles relate to specific phenotypes and endotypes are not well understood.NOVELTY (a NOVEL observational longiTudinal studY in patients with asthma and/ or COPD; clinicaltrials.govNCT02760329) aims to describe patient characteristics, treatment patterns and disease burden across the spectrum of asthma and COPD over time, and to identify phenotypes and molecular endotypes associated with differential outcomes for symptom burden, clinical evolution and healthcare utilisation (HCU).Method: NOVELTY is a global, prospective, observational, longitudinal cohort study that will include up to 12,000 patients ≥12 years of age with a diagnosis or suspected diagnosis of asthma and/or COPD across the spectrum of severities (balanced across diagnoses and severities), from primary and specialist care.The study will collect data on clinical assessments, spirometry, biospecimens (blood and urine), patient-reported outcomes (PROs) and HCU at baseline and longitudinally for 3 years.Data captured at annual visits will be recorded in study-specific electronic case report forms, with some PROs and HCU data collected remotely every 3 months.Recruitment is expected to end in March 2018 (except in China), followed by baseline analysis.Results: NOVELTY will provide a rich data source that may enable novel classification of patients across the spectrum of obstructive lung disease according to clinical outcomes, PROs and biomarker profiles over time.It will create a biobank and data platform of evidence from clinical practice, which can also be utilised in the future by the broader community of physicians, patients, regulators and the scientific community.Conclusion: Results from NOVELTY will provide insights into the diagnosis, assessment and management of patients with asthma and/or COPD in primary and specialist care around the world and may help support the future development of novel therapies and personalised healthcare in obstructive lung disease.The data platform created by NOVELTY will also be a valuable resource for research beyond the core objectives of the study itself.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Science and technology studies, Insufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.193
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0080.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.002
Science and technology studies0.0010.004
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0020.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.100
GPT teacher head0.395
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueRespiratory ResearchSame topicChronic Obstructive Pulmonary Disease (COPD) ResearchFrench-language works237,207